Informations sur le produit
- (1R,2S,5S)-N-[(1S)-1-[(Cyclopropylamino)oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
- 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1S)-1-[(cyclopropylamino)oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-
- 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-
- Sch 900518
Narlaprevir is a protease inhibitor that inhibits the activity of HIV proteases, which are enzymes that cleave viral polyproteins into individual proteins. Narlaprevir has been shown to inhibit the replication of wild-type and resistant HIV-1 mutants in cells. In addition, this drug has pharmacokinetic properties that allow it to be taken orally. This antiviral agent is a nucleoside analogue with a half-life of 12 hours and has been shown to be effective against chronic viral hepatitis.